Cargando…

Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors

Salivary gland tumors (SGTs) comprise a group of rare neoplasms. Locally aggressive, recurrent and/or metastatic SGTs are notorious for their resistance to systemic therapy, making the need for carefully designed, prospective and randomized trials with useful predictive markers mandatory to define n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pouloudi, Despoina, Manou, Maria, Sarantis, Panagiotis, Tsoukalas, Nikolaos, Tsourouflis, Gerasimos, Dana, Eougken, Karamouzis, Michalis V., Klijanienko, Jerzy, Theocharis, Stamatios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000873/ https://www.ncbi.nlm.nih.gov/pubmed/33799478 http://dx.doi.org/10.3390/diagnostics11030517

Ejemplares similares

The Impact of Angiogenesis in the Most Common Salivary Gland Malignant Tumors
por: Pouloudi, Despoina, et al.
Publicado: (2020)

Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients’ Survival
por: Levidou, Georgia, et al.
Publicado: (2021)

Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
por: Goutas, Dimitrios, et al.
Publicado: (2021)

Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options
por: Manou, Maria, et al.
Publicado: (2023)

Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
por: Garmpis, Nikolaos, et al.
Publicado: (2022)

Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
por: Palamaris, Kostas, et al.
Publicado: (2022)

The Controversial Role of Autophagy in Ewing Sarcoma Pathogenesis—Current Treatment Options
por: Koustas, Evangelos, et al.
Publicado: (2021)

Enhanced Transcriptional Signature and Expression of Histone-Modifying Enzymes in Salivary Gland Tumors
por: Manou, Maria, et al.
Publicado: (2023)

Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: An immunohistochemical study
por: Giaginis, Constantinos, et al.
Publicado: (2011)

RCAS1 expression in mobile tongue squamous cell carcinoma: An immunohistochemical study
por: Theocharis, Stamatios, et al.
Publicado: (2011)

Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival
por: Giaginis, Constantinos, et al.
Publicado: (2015)

Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors
por: Palamaris, Kostas, et al.
Publicado: (2023)

High Pregnane X Receptor (PXR) Expression Is Correlated with Poor Prognosis in Invasive Breast Carcinoma
por: Theocharis, Stamatios, et al.
Publicado: (2021)

Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules
por: Vallilas, Christos, et al.
Publicado: (2021)

HuR Protein in Hepatocellular Carcinoma: Implications in Development, Prognosis and Treatment
por: Papatheofani, Vasiliki, et al.
Publicado: (2021)

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
por: Zoi, Ilianna, et al.
Publicado: (2019)

Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
por: Garmpis, Nikolaos, et al.
Publicado: (2021)

Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?
por: Georgantzoglou, Natalia, et al.
Publicado: (2021)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Psilopatis, Iason, et al.
Publicado: (2021)

Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway
por: Siatis, Konstantinos E., et al.
Publicado: (2023)

EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer
por: Nikas, Ilias, et al.
Publicado: (2022)

The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy
por: Psilopatis, Iason, et al.
Publicado: (2023)

Hepatic encephalopathy: An updated approach from pathogenesis to treatment
por: Toris, Giannakis T., et al.
Publicado: (2011)

The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient Management
por: Psilopatis, Iason, et al.
Publicado: (2022)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer
por: Xu, Xiaoxin S, et al.
Publicado: (2011)

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
por: Bassett, Shalome A., et al.
Publicado: (2014)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

Clinical and Molecular Insights of Radiation-Induced Breast Sarcomas: Is There Hope on the Horizon for Effective Treatment of This Aggressive Disease?
por: Kokkali, Stefania, et al.
Publicado: (2022)

Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer
por: Sarantis, Panagiotis, et al.
Publicado: (2021)

CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2
por: Boucheron, Nicole, et al.
Publicado: (2014)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: An immunohistochemical study
por: Karidis, Nikolaos P., et al.
Publicado: (2011)

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
por: Wagner, Julia M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_hespip6o1pt353pu3hrsk0cbv2